AI-ACCELERATED DRUG DISCOVERY

Focused On-demand Library for Myozenin-2

Available from Reaxense
Predicted by Alphafold

Focused On-demand Libraries - Reaxense Collaboration

Explore the Potential with AI-Driven Innovation

Our detailed focused library is generated on demand with advanced virtual screening and parameter assessment technology powered by the Receptor.AI drug discovery platform. This method surpasses traditional approaches, delivering compounds of better quality with enhanced activity, selectivity, and safety.

We pick out particular compounds from an extensive virtual database of more than 60 billion molecules. The preparation and shipment of these compounds are facilitated by our associate Reaxense.

The library includes a list of the most promising modulators annotated with 38 ADME-Tox and 32 physicochemical and drug-likeness parameters. Also, each compound is presented with its optimal docking poses, affinity scores, and activity scores, providing a comprehensive overview.

We employ our advanced, specialised process to create targeted libraries.

 Fig. 1. The sreening workflow of Receptor.AI

Our methodology employs molecular simulations to explore a wide array of proteins, capturing their dynamic states both individually and within complexes. Through ensemble virtual screening, we address conformational mobility, uncovering binding sites within functional regions and remote allosteric locations. This thorough exploration ensures no potential mechanism of action is overlooked, aiming to discover novel therapeutic targets and lead compounds across an extensive spectrum of biological functions.

Our library stands out due to several important features:

  • The Receptor.AI platform compiles comprehensive data on the target protein, encompassing previous experiments, literature, known ligands, structural details, and more, leading to a higher chance of selecting the most relevant compounds.
  • Advanced molecular simulations on the platform help pinpoint potential binding sites, making the compounds in our focused library ideal for finding allosteric inhibitors and targeting cryptic pockets.
  • Receptor.AI boasts over 50 tailor-made AI models, rigorously tested and proven in various drug discovery projects and research initiatives. They are crafted for efficacy, dependability, and precision, all of which are key in creating our focused libraries.
  • Beyond creating focused libraries, Receptor.AI offers comprehensive services and complete solutions throughout the preclinical drug discovery phase. Our success-based pricing model minimises risk and maximises the mutual benefits of the project's success.

partner

Reaxense

upacc

Q9NPC6

UPID:

MYOZ2_HUMAN

Alternative names:

Calsarcin-1; FATZ-related protein 2

Alternative UPACC:

Q9NPC6; O43415; Q9HB92

Background:

Myozenin-2, also known as Calsarcin-1 or FATZ-related protein 2, plays a pivotal role in cardiac muscle function. It acts as an intracellular binding protein, linking Z line proteins such as alpha-actinin and gamma-filamin, and is crucial in localizing calcineurin signaling to the sarcomere. This protein is instrumental in myofibrillogenesis, the process of myofibril formation, which is essential for muscle structure and function.

Therapeutic significance:

Myozenin-2 is implicated in Cardiomyopathy, familial hypertrophic, 16, a hereditary heart disorder characterized by ventricular hypertrophy. Understanding the role of Myozenin-2 could open doors to potential therapeutic strategies for managing this condition, which can lead to cardiac failure and sudden cardiac death.

Looking for more information on this library or underlying technology? Fill out the form below and we'll be in touch with all the details you need.
Thank you! Your submission has been received!
Oops! Something went wrong while submitting the form.
No Spam. Cancel Anytime.